Natus Medical (NASDAQ:BABY) & Newcardio (NASDAQ:NWCI) Head-To-Head Review

Natus Medical (NASDAQ:BABY) and Newcardio (OTCMKTS:NWCI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, valuation, earnings and analyst recommendations.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Natus Medical and Newcardio, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natus Medical 0 1 1 0 2.50
Newcardio 0 0 0 0 N/A



Natus Medical presently has a consensus target price of $36.00, indicating a potential upside of 37.14%. Given Natus Medical’s higher probable upside, research analysts plainly believe Natus Medical is more favorable than Newcardio.

Valuation and Earnings

This table compares Natus Medical and Newcardio’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Natus Medical $530.89 million 1.68 -$22.93 million $1.42 18.49
Newcardio N/A N/A N/A N/A N/A

Newcardio has lower revenue, but higher earnings than Natus Medical.

Profitability

This table compares Natus Medical and Newcardio’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Natus Medical -8.62% 10.75% 6.56%
Newcardio N/A N/A N/A

Insider & Institutional Ownership

91.6% of Natus Medical shares are held by institutional investors. 1.7% of Natus Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Natus Medical has a beta of 0.57, suggesting that its stock price is 43% less volatile than the S&P 500. Comparatively, Newcardio has a beta of 6.41, suggesting that its stock price is 541% more volatile than the S&P 500.

Summary

Natus Medical beats Newcardio on 7 of the 9 factors compared between the two stocks.

Natus Medical Company Profile

Natus Medical Incorporated provides neurology, newborn care, and hearing and balance assessment healthcare products and services worldwide. It offers products and services used for the screening, diagnosis, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction and neurosurgical treatments, epilepsy, sleep disorders, neuromuscular diseases, and balance and mobility disorders. The company also provides computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology; and software systems for managing and tracking disorders and diseases for public health laboratories. In addition, it offers electroencephalography, long term monitoring, intensive care unit monitoring, electromyography, sleep analysis or polysomnography, and intra-operative monitoring solutions. Further, the company provides hearing screening products; diagnostic hearing assessment products to screen for/or diagnose hearing loss, or to identify abnormalities affecting the peripheral and central auditory nervous systems; balance and mobility systems to diagnose and assist in treating balance disorders; and thermoregulation products to control the incubators and warmers. Additionally, it offers jaundice management products; brain injury products; NICVIEW, a live streaming video for families with babies in the neonatal intensive care unit (NICU); essential products used in the everyday operation of NICU; and eye imaging systems and products used in the advanced science and practice of neonatal and pediatric retinal imaging. The company also provides computer-based audiological, otoneurologic, and vestibular instrumentation and sound rooms to hearing and balance care professionals. It serves hospitals, clinics, laboratories, physicians, nurses, audiologists, and governmental agencies. Natus Medical Incorporated was incorporated in 1987 and is headquartered in Pleasanton, California.

Newcardio Company Profile

NewCardio, Inc., a cardiac diagnostic and services company, focuses on the research, development, and commercialization of proprietary software platform technology solutions for the non-invasive diagnosis and monitoring of cardiovascular disease (CVD), as well as the cardiac safety assessment of drugs under development. The company's technology platform provides real-time and 3-D analysis of the heart's electrical activity as detected at the body surface by standard 12-lead electrocardiogram (ECG) electrodes. Its developing products include QTinno, an automated cardiac safety solution that replaces the manual and/or semi-automated methodologies with algorithms that automatically measure, analyze, and report on the ECGs collected; and CardioBip, a mobile ECG transtelephonic system comprising a mobile ECG recording and transmitting device, and a Web enabled software which receives, processes, and analyzes the data. The company is also developing my3KG, a software application to provide a method to assess cardiac electrical activity in time and space. NewCardio, Inc. was founded in 2004 and is based in Branchburg, New Jersey.

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.